Chronic Pancreatitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Chronic pancreatitis is a progressive inflammatory condition that results in the irreversible destruction of both exocrine and endocrine pancreatic tissue, typically due to atrophy or its replacement with fibrous tissue. This disorder gives rise to significant functional consequences, including intense abdominal pain, diabetes mellitus, and malabsorption of nutrients. Chronic pancreatitis can be triggered by various factors, including alcohol abuse, blockage of the pancreatic ducts (caused by malignancies, stones, or trauma), genetic predisposition, chemotherapy, and autoimmune diseases such as systemic lupus erythematosus (SLE) or autoimmune pancreatitis. Laboratory tests used for diagnosing chronic pancreatitis encompass a complete blood count (CBC), basic metabolic panel (BMP), liver function tests (LFTs), lipase, amylase, lipid panel, and measurement of fecal elastase-1 levels. Lipase and amylase levels may exhibit elevation, although they tend to be normal due to significant pancreatic scarring and fibrosis. The primary goal of treatment includes reducing abdominal pain and addressing malabsorption. The pain experienced by individuals with chronic pancreatitis arises from inflammation, neuropathic mechanisms, and obstructed ducts. Dietary recommendations typically involve consuming small, frequent, low-fat meals and supplementing fat-soluble vitamins and pancreatic enzymes. Surgical intervention to resect the pancreas can yield positive outcomes when performed by experienced surgeons. However, it's worth noting that the procedure carries a mortality rate exceeding 10%, and the quality of life is compromised without a properly functioning pancreas. In cases where there is persistent and worsening abdominal pain, a comprehensive differential diagnosis is considered. This includes conditions such as peptic ulcer disease, cholelithiasis, biliary obstruction or colic, acute pancreatitis, pancreatic malignancy, pseudocyst formation, and chronic mesenteric ischemia. The prognosis for chronic pancreatitis is significantly affected by ongoing alcohol use, smoking, and end-stage liver disease. Ten years after diagnosis, there is a survival rate of 70%, which decreases to 45% at the 20-year mark. Notable complications include pseudocyst formation and mechanical obstructions of the bile duct and duodenum.

·       In the United States, the annual incidence of chronic pancreatitis is approximately 24.7 cases per 100,000 individuals in the adult population and 1.9 cases per 100,000 in the pediatric population.

 

Thelansis’s “Chronic Pancreatitis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Pancreatitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Chronic Pancreatitis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chronic Pancreatitis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Chronic Pancreatitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Chronic Pancreatitis, Chronic Pancreatitis market outlook, Chronic Pancreatitis competitive landscape, Chronic Pancreatitis market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)